Our Perspective

• 

  Collaboration Can Bring Digital Innovation to Life Insurance

  By Ross Campbell |January 23, 2018|English | Deutsch

  There is a view that the life insurance business needs to change or to innovate in order to remain relevant and reach new customers; if incumbent players don’t make an environment that appeals to new customers, someone else will step in and do...

  Read More
• 

  Treating Ageing to Extend a Healthy Lifespan

  By Beata Puls |December 20, 2017|English

  Life expectancy has increased remarkably in the last few decades. The number of people living to or even beyond age 100 is expected to increase. This puts ageing at centre stage alongside healthy life expectancy – meaning the years an ageing person...

  Read More
• 

  Stroke in Younger Adults - Have Improvements Reached Their Limit?

  By Dr. Chris Ball |December 18, 2017|English

  Age remains the most consistent risk factor for ischaemic stroke. Surprisingly then an estimated 10% of diagnoses are now seen in people below the age of 50. In many countries vigorous management of vascular risk coupled to improved stroke services...

  Read More
• 

  Lump Sum Benefits - The Experience in New Zealand

  By Li Wen Beh and Winncy Wong |November 28, 2017|English

  Gen Re has conducted various experience investigations of the New Zealand Life, Disability and Critical Illness markets. Our latest survey of fully-underwritten individual Life and Trauma (Critical Illness) cover offers the first-ever insights to Total...

  Read More
• 

  Progress in the Management of Multiple Sclerosis

  By Dr. Chris Ball |November 23, 2017|English

  Multiple Sclerosis (MS) presents a challenge to insurers due to its complex, unpredictable course. MS is a covered condition in “Critical Illness” insurance policies sold in markets across Asia, in the UK and Ireland, South Africa, New Zealand...

  Read More
• 

  Genetic Testing and the Power of Knowledge

  By Annika Tiedemann |November 16, 2017|English

  Using genetic testing to make treatment decisions on serious medical conditions, such as cancer, is becoming more common. Approved tests number in the thousands, and the costs associated with genome sequencing have fallen sharply. Most genetic tests...

  Read More